- Home
- CNOB vs EYPT Comparison
CNOB vs EYPT Comparison
Compare CNOB & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNOB | EYPT |
|---|---|---|
| Founded | 1982 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | CNOB | EYPT |
|---|---|---|
| Price | $27.82 | $17.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $30.00 | $28.75 |
| AVG Volume (30 Days) | 264.6K | ★ 1.6M |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $40.08 | N/A |
| Revenue Next Year | $7.27 | N/A |
| P/E Ratio | $17.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.61 | $3.91 |
| 52 Week High | $29.28 | $19.11 |
Technical Indicators
Market Signals| Indicator | CNOB | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.28 | 67.39 |
| Support Level | $25.16 | $11.88 |
| Resistance Level | $28.85 | $19.06 |
| Average True Range (ATR) | 0.88 | 1.20 |
| MACD | -0.07 | 0.59 |
| Stochastic Oscillator | 56.70 | 98.04 |
Price Performance
Historical ComparisonAbout CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.